Neo Ivy Capital Management Intra Cellular Therapies, Inc. Transaction History

Neo Ivy Capital Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 29, 2023	BUY	$52.09 - $64.1 $45,422 - $55,895	872 New	872 $45,000
Q3 2021 Nov 16, 2021	SELL	$28.72 - $42.49 $98,251 - $145,358	-3,421 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $100,235 - $152,234	3,421 New	3,421 $140,000
Q1 2021 Oct 07, 2021	SELL	$30.8 - $39.51 $107,646 - $138,087	-3,495 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $61,220 - $84,513	2,623 Added 300.8%	3,495 $111,000
Q3 2020 Nov 17, 2020	BUY	$17.61 - $31.86 $15,355 - $27,781	872 New	872 $22,000

381

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.